CXCR4 antagonists, such as Plerixafor (AMD3100) and T140 analogues (TN14003/BKT140), can disrupt CXCR4-mediated tumor cell adhesion to stromal cells and sensitize lung cancer cells to cytotoxic drugs.[19] Study in head and neck squamous cell carcinoma showed that IFN-γ could also significantly reduce the expression of CXCR4.[20]. Here, CXCR4 is linked to head and neck squamous cell carcinoma.